Sizes of these terms reflect their relevance to your search.
Vor Biopharma secured $110 million in July to move its CD33-inactivated cell therapy into clinical testing. The company's hope is that patients with high-risk acute myeloid leukemia who receive transplants of the gene-edited stem cells will then better tolerate therapies designed to destroy cells expressing CD33, an antigen found in abundance on leukemic blasts. ©2020 American Association for Cancer Research.
Citation
Vor Nets $110m to Make Anti-CD33 Drugs Safer. Cancer discovery. 2020 Sep;10(9):1248-1249
PMID: 32747379
View Full Text
